Symbols / LTRN
LTRN Chart
About
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 27.85M |
| Enterprise Value | 16.48M | Income | -18.92M | Sales | — |
| Book/sh | 0.87 | Cash/sh | 1.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | — | Forward P/E | -1.30 | PEG | — |
| P/S | — | P/B | 2.87 | P/C | — |
| EV/EBITDA | -0.84 | EV/Sales | — | Quick Ratio | 3.06 |
| Current Ratio | 3.33 | Debt/Eq | 0.98 | LT Debt/Eq | — |
| EPS (ttm) | -1.75 | EPS next Y | -1.91 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -55.99% |
| ROE | -104.58% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.18M |
| Shs Float | 8.59M | Short Float | 2.76% | Short Ratio | 5.16 |
| Short Interest | — | 52W High | 5.74 | 52W Low | 2.51 |
| Beta | 1.52 | Avg Volume | 59.06K | Volume | 5.27K |
| Target Price | $20.00 | Recom | None | Prev Close | $2.59 |
| Price | $2.49 | Change | -3.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.00
Mean price target
2. Current target
$2.49
Latest analyst target
3. DCF / Fair value
$-15.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.49
Low
$15.00
High
$25.00
Mean
$20.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-02 | init | Lake Street | — → Buy | $25 |
| 2024-04-25 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-08-10 | reit | EF Hutton | Buy → Buy | $11 |
| 2023-06-26 | main | EF Hutton | Buy → Buy | $11 |
| 2023-05-18 | init | HC Wainwright & Co. | — → Neutral | — |
| 2023-03-21 | reit | EF Hutton | — → Buy | $11 |
| 2023-02-15 | main | EF Hutton | — → Buy | $11 |
| 2022-11-01 | init | EF Hutton | — → Buy | $11 |
| 2022-03-11 | main | HC Wainwright & Co. | — → Buy | $36 |
| 2021-11-02 | main | HC Wainwright & Co. | — → Buy | $34 |
| 2021-10-07 | init | HC Wainwright & Co. | — → Buy | $32 |
| 2020-07-28 | init | Colliers Securities | — → Buy | $24 |
- FDA orphan status for Lantern drug targets 96,000 soft tissue sarcoma cases - Stock Titan ue, 20 Jan 2026 08
- Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely - Yahoo Finance Sat, 15 Nov 2025 08
- Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - simplywall.st Fri, 21 Nov 2025 08
- LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView ue, 08 Jul 2025 07
- Earnings call transcript: Lantern Pharma Q3 2025 sees stock rise after earnings - Investing.com hu, 13 Nov 2025 08
- AI-powered brain cancer drug from Lantern to be detailed at Boston summit - Stock Titan ue, 10 Feb 2026 08
- Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Insider Monkey hu, 12 Feb 2026 16
- Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Yahoo Finance Sat, 31 May 2025 07
- Aug Levels: What’s the analyst consensus on LTRN - Market Risk Analysis & Verified Stock Trade Ideas - mfd.ru Sun, 15 Feb 2026 12
- 2 sub‑$10 AI stocks to outperform Palantir in 2026, according to ChatGPT‑5 - Finbold Sun, 23 Nov 2025 08
- Lantern Pharma (NASDAQ: LTRN) posts LP-184 Phase 1a data, eyes biomarker-guided Phase 1b/2 - Stock Titan Wed, 03 Dec 2025 08
- Breakthrough: Advanced Lung Cancer Patient Achieves Complete Response After 3 Failed Therapies - Stock Titan Mon, 16 Jun 2025 07
- Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire - Yahoo Finance Sat, 31 Aug 2024 07
- LTRN Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 02
- Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development - Yahoo Finance Fri, 17 Jan 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40000 | 123600 | — | Sale at price 3.09 per share. | KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-13 00:00:00 | I |
| 1 | 61613 | 208271 | — | Sale at price 3.38 - 3.40 per share. | KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-12 00:00:00 | I |
| 2 | 56237 | 168419 | — | Sale at price 2.87 - 3.05 per share. | KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-29 00:00:00 | I |
| 3 | 3832 | 16937 | — | Conversion of Exercise of derivative security at price 4.42 per share. | KEYSER DONALD JEFFREY PH.D | Director | — | 2024-07-24 00:00:00 | D |
| 4 | 30000 | 189100 | — | Sale at price 6.25 - 6.33 per share. | KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-24 00:00:00 | I |
| 5 | 144000 | 676294 | — | Sale at price 4.40 - 4.87 per share. | KREIS LESLIE W JR | Beneficial Owner of more than 10% of a Class of Security | — | 2024-02-29 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -22.20M | -17.86M | -14.42M | -12.58M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.78M | -15.96M | -14.26M | -12.36M |
| ReconciledDepreciation | 17.28K | 14.62K | 10.08K | 6.76K |
| EBITDA | -22.20M | -17.86M | -14.42M | -12.58M |
| EBIT | -22.22M | -17.88M | -14.43M | -12.59M |
| NetInterestIncome | 742.36K | 765.39K | 204.35K | 67.93K |
| InterestIncome | 742.36K | 765.39K | 204.35K | 67.93K |
| NormalizedIncome | -20.78M | -15.96M | -14.26M | -12.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.78M | -15.96M | -14.26M | -12.36M |
| TotalExpenses | 22.22M | 17.88M | 14.43M | 12.59M |
| TotalOperatingIncomeAsReported | -22.22M | -17.88M | -14.43M | -12.59M |
| DilutedAverageShares | 10.76M | 10.84M | 10.85M | 10.90M |
| BasicAverageShares | 10.76M | 10.84M | 10.85M | 10.90M |
| DilutedEPS | -1.93 | -1.47 | -1.31 | -1.13 |
| BasicEPS | -1.93 | -1.47 | -1.31 | -1.13 |
| DilutedNIAvailtoComStockholders | -20.78M | -15.96M | -14.26M | -12.36M |
| NetIncomeCommonStockholders | -20.78M | -15.96M | -14.26M | -12.36M |
| NetIncome | -20.78M | -15.96M | -14.26M | -12.36M |
| NetIncomeIncludingNoncontrollingInterests | -20.78M | -15.96M | -14.26M | -12.36M |
| NetIncomeContinuousOperations | -20.78M | -15.96M | -14.26M | -12.36M |
| PretaxIncome | -20.78M | -15.96M | -14.26M | -12.36M |
| OtherIncomeExpense | 692.87K | 1.15M | -31.55K | 160.55K |
| OtherNonOperatingIncomeExpenses | 692.87K | 1.15M | -31.55K | 160.55K |
| NetNonOperatingInterestIncomeExpense | 742.36K | 765.39K | 204.35K | 67.93K |
| InterestIncomeNonOperating | 742.36K | 765.39K | 204.35K | 67.93K |
| OperatingIncome | -22.22M | -17.88M | -14.43M | -12.59M |
| OperatingExpense | 22.22M | 17.88M | 14.43M | 12.59M |
| ResearchAndDevelopment | 16.13M | 11.89M | 8.60M | 7.57M |
| SellingGeneralAndAdministration | 6.09M | 5.98M | 5.83M | 5.02M |
| GeneralAndAdministrativeExpense | 6.09M | 5.98M | 5.83M | 5.02M |
| OtherGandA | 6.09M | 5.98M | 5.83M | 5.02M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 10.78M | 10.72M | 10.86M | 11.09M |
| ShareIssued | 10.78M | 10.72M | 10.86M | 11.09M |
| TotalDebt | 243.66K | 234.47K | 52.89K | 204.95K |
| TangibleBookValue | 21.19M | 40.91M | 56.04M | 71.57M |
| InvestedCapital | 21.19M | 40.91M | 56.04M | 71.57M |
| WorkingCapital | 20.92M | 40.66M | 55.92M | 70.39M |
| NetTangibleAssets | 21.19M | 40.91M | 56.04M | 71.57M |
| CapitalLeaseObligations | 243.66K | 234.47K | 52.89K | 204.95K |
| CommonStockEquity | 21.19M | 40.91M | 56.04M | 71.57M |
| TotalCapitalization | 21.19M | 40.91M | 56.04M | 71.57M |
| TotalEquityGrossMinorityInterest | 21.19M | 40.91M | 56.04M | 71.57M |
| StockholdersEquity | 21.19M | 40.91M | 56.04M | 71.57M |
| GainsLossesNotAffectingRetainedEarnings | 153.99K | -107.46K | -371.39K | -92.69K |
| OtherEquityAdjustments | 153.99K | -107.46K | -371.39K | -92.69K |
| RetainedEarnings | -76.03M | -55.24M | -39.28M | -25.02M |
| AdditionalPaidInCapital | 97.06M | 96.26M | 95.69M | 96.69M |
| CapitalStock | 1.08K | 1.07K | 1.09K | 1.11K |
| CommonStock | 1.08K | 1.07K | 1.09K | 1.11K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.38M | 2.74M | 2.80M | 2.38M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 52.84K | 61.50K | 0.00 | 52.89K |
| LongTermDebtAndCapitalLeaseObligation | 52.84K | 61.50K | 0.00 | 52.89K |
| LongTermCapitalLeaseObligation | 52.84K | 61.50K | 0.00 | 52.89K |
| CurrentLiabilities | 4.33M | 2.68M | 2.80M | 2.33M |
| CurrentDebtAndCapitalLeaseObligation | 190.81K | 172.97K | 52.89K | 152.06K |
| CurrentCapitalLeaseObligation | 190.81K | 172.97K | 52.89K | 152.06K |
| PayablesAndAccruedExpenses | 4.14M | 2.51M | 2.75M | 2.17M |
| TotalAssets | 25.57M | 43.65M | 58.84M | 73.95M |
| TotalNonCurrentAssets | 324.16K | 306.29K | 113.58K | 1.23M |
| OtherNonCurrentAssets | 36.74K | 25.87K | 17.89K | 1.02M |
| NonCurrentDeferredAssets | 0.00 | |||
| NetPPE | 287.43K | 280.42K | 95.69K | 216.19K |
| GrossPPE | 287.43K | 280.42K | 95.69K | 216.19K |
| OtherProperties | 287.43K | 280.42K | 95.69K | 216.19K |
| CurrentAssets | 25.25M | 43.34M | 58.72M | 72.72M |
| OtherCurrentAssets | 1.23M | 2.04M | 2.99M | 1.99M |
| RestrictedCash | 0.00 | 541.18K | 0.00 | |
| PrepaidAssets | 2.99M | 1.99M | ||
| CashCashEquivalentsAndShortTermInvestments | 24.01M | 41.30M | 55.20M | 70.73M |
| OtherShortTermInvestments | 16.50M | 19.36M | 17.99M | 19.20M |
| CashAndCashEquivalents | 7.51M | 21.94M | 37.20M | 51.52M |
| CashEquivalents | 6.62M | 20.88M | 1.27M | |
| CashFinancial | 892.08K | 1.06M | 35.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -17.83M | -14.37M | -12.80M | -10.61M |
| RepurchaseOfCapitalStock | -500.00K | -2.48M | -939.67K | |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 69.00M | ||
| CapitalExpenditure | -12.60K | -18.73K | -27.84K | -15.50K |
| EndCashPosition | 7.51M | 21.94M | 37.74M | 52.52M |
| BeginningCashPosition | 21.94M | 37.74M | 52.52M | 19.23M |
| EffectOfExchangeRateChanges | -49.55K | -28.46K | -10.61K | 1.07K |
| ChangesInCash | -14.38M | -15.78M | -14.77M | 33.29M |
| FinancingCashFlow | 66.71K | -500.00K | -2.18M | 63.42M |
| CashFlowFromContinuingFinancingActivities | 66.71K | -500.00K | -2.18M | 63.42M |
| NetOtherFinancingCharges | -500.00K | -4.78M | ||
| ProceedsFromStockOptionExercised | 66.71K | 0.00 | 299.79K | 139.61K |
| NetPreferredStockIssuance | -2.48M | -939.67K | ||
| PreferredStockPayments | -2.48M | -939.67K | ||
| NetCommonStockIssuance | -500.00K | -2.48M | 69.00M | |
| CommonStockPayments | -500.00K | -2.48M | ||
| CommonStockIssuance | 0.00 | 69.00M | ||
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 3.37M | -930.21K | 179.27K | -19.53M |
| CashFlowFromContinuingInvestingActivities | 3.37M | -930.21K | 179.27K | -19.53M |
| NetInvestmentPurchaseAndSale | 3.38M | -911.48K | 207.11K | -19.52M |
| SaleOfInvestment | 20.66M | 7.28M | 4.12M | 64.09K |
| PurchaseOfInvestment | -17.28M | -8.20M | -3.91M | -19.58M |
| NetPPEPurchaseAndSale | -12.60K | -18.73K | -27.84K | -15.50K |
| PurchaseOfPPE | -12.60K | -18.73K | -27.84K | -15.50K |
| OperatingCashFlow | -17.81M | -14.35M | -12.77M | -10.59M |
| CashFlowFromContinuingOperatingActivities | -17.81M | -14.35M | -12.77M | -10.59M |
| ChangeInWorkingCapital | 2.23M | 538.02K | -611.86K | 599.96K |
| ChangeInOtherCurrentLiabilities | -175.72K | -159.25K | -158.40K | -71.66K |
| ChangeInOtherCurrentAssets | -10.87K | -7.98K | 0.00 | 33.99K |
| ChangeInPayablesAndAccruedExpense | 1.64M | -236.18K | 580.36K | 1.62M |
| ChangeInPrepaidAssets | 778.30K | 941.44K | -1.03M | -984.46K |
| OtherNonCashItems | 173.21K | 160.23K | 144.60K | 90.66K |
| StockBasedCompensation | 732.89K | 1.07M | 1.19M | 961.54K |
| UnrealizedGainLossOnInvestmentSecurities | -155.62K | -119.65K | 492.50K | 80.56K |
| AmortizationOfSecurities | -238.57K | -173.09K | 81.87K | 140.51K |
| DepreciationAmortizationDepletion | 17.28K | 14.62K | 10.08K | 6.76K |
| DepreciationAndAmortization | 17.28K | 14.62K | 10.08K | 6.76K |
| OperatingGainsLosses | 210.66K | 127.34K | 187.52K | -108.50K |
| GainLossOnInvestmentSecurities | -9.06K | 115.84K | 128.92K | 80.56K |
| NetForeignCurrencyExchangeGainLoss | 219.73K | 11.50K | 58.60K | 0.00 |
| NetIncomeFromContinuingOperations | -20.78M | -15.96M | -14.26M | -12.36M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for LTRN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|